Skip to main content
Erschienen in: Current Infectious Disease Reports 6/2015

01.06.2015 | Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

Sepsis in the Severely Immunocompromised Patient

verfasst von: Andre C. Kalil, Steven M. Opal

Erschienen in: Current Infectious Disease Reports | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

The prevention and treatment of sepsis in the immunocompromised host present a challenging array of diagnostic and management issues. The neutropenic patient has a primary defect in innate immune responses and is susceptible to conventional and opportunistic pathogens. The solid organ transplant patient has a primary defect in adaptive immunity and is susceptible to a myriad of pathogens that require an effective cellular immune response. Risk for infections in organ transplant recipients is further complicated by mechanical, vascular, and rejection of the transplanted organ itself. The immune suppressed state can modify the cardinal signs of inflammation, making accurate and rapid diagnosis of infection and sepsis difficult. Empiric antimicrobial agents can be lifesaving in these patients, but managing therapy in an era of progressive antibiotic resistance has become a real issue. This review discusses the challenges faced when treating severe infections in these high-risk patients.
Literatur
1.
Zurück zum Zitat Angus DC, van der Poll T. Severe sepsis and septic shock. 2013; 369: 840-852. Angus DC, van der Poll T. Severe sepsis and septic shock. 2013; 369: 840-852.
2.
Zurück zum Zitat Legrand M, Max A, Peigne V, et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med. 2012;40(1):43–9.CrossRefPubMed Legrand M, Max A, Peigne V, et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med. 2012;40(1):43–9.CrossRefPubMed
3.
Zurück zum Zitat Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):e56–93.CrossRefPubMed Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):e56–93.CrossRefPubMed
4.
Zurück zum Zitat Kern WV. Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis. 2006;42(2):533–40.CrossRefPubMed Kern WV. Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis. 2006;42(2):533–40.CrossRefPubMed
5.
Zurück zum Zitat Jeddi R, Achour M, Amor RB, et al. Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes. Hematology. 2010;15(1):23–32.CrossRef Jeddi R, Achour M, Amor RB, et al. Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes. Hematology. 2010;15(1):23–32.CrossRef
6.•
Zurück zum Zitat Kalil AC, Syed A, Rupp ME, et al. Is bacteremic sepsis associated with higher mortality in transplant recipients than in nontransplant patients? A matched case-control propensity-adjusted study. Clin Infect Dis. 2015;60(2):216–22. This study compared patients who had a solid organ transplant and sepsis to patients who did not have organ transplant but had sepsis. They were matched by age, gender, and hospital unit location at the time of blood culture collection. The results showed a statistically significant higher survival rates for septic patients who had organ transplantation than that those without transplantation, after accounting for disease severity and co-morbidities.CrossRefPubMed Kalil AC, Syed A, Rupp ME, et al. Is bacteremic sepsis associated with higher mortality in transplant recipients than in nontransplant patients? A matched case-control propensity-adjusted study. Clin Infect Dis. 2015;60(2):216–22. This study compared patients who had a solid organ transplant and sepsis to patients who did not have organ transplant but had sepsis. They were matched by age, gender, and hospital unit location at the time of blood culture collection. The results showed a statistically significant higher survival rates for septic patients who had organ transplantation than that those without transplantation, after accounting for disease severity and co-morbidities.CrossRefPubMed
7.•
Zurück zum Zitat Penack O, Becker C, Buchheidt M, et al. Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases working party of the German Society of Hematology and Medical Oncology. Ann Hematol. 2014;93(7):1083–95. This evidence-based review is the most recent national set of guidelines established as a set of recommendations to manage the febrile neutropenic patient. The guideline favors early antibiotic therapy directed towards the most likely pathogens with appropriate therapy guided by local susceptibilty patterns of common bacterial pathogens. Penack O, Becker C, Buchheidt M, et al. Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases working party of the German Society of Hematology and Medical Oncology. Ann Hematol. 2014;93(7):1083–95. This evidence-based review is the most recent national set of guidelines established as a set of recommendations to manage the febrile neutropenic patient. The guideline favors early antibiotic therapy directed towards the most likely pathogens with appropriate therapy guided by local susceptibilty patterns of common bacterial pathogens.
8.
Zurück zum Zitat Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan. Clin Infect Dis. 2004;39 Suppl 1:S49.CrossRefPubMed Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan. Clin Infect Dis. 2004;39 Suppl 1:S49.CrossRefPubMed
9.
Zurück zum Zitat Viscoli C on behalf of the EORTC international antimicrobial therapy group. Management of infection in cancer patients. Euro J Cancer. 2002;38 suppl 4:82–7. Viscoli C on behalf of the EORTC international antimicrobial therapy group. Management of infection in cancer patients. Euro J Cancer. 2002;38 suppl 4:82–7.
10.
Zurück zum Zitat Legrand M, Max A, Schlemmer B, Azoulay E, Gachot B. The strategy of antibiotic use in critically ill neutropenic cancer patients. Ann Intensive Care. 2011;1:1–22.CrossRef Legrand M, Max A, Schlemmer B, Azoulay E, Gachot B. The strategy of antibiotic use in critically ill neutropenic cancer patients. Ann Intensive Care. 2011;1:1–22.CrossRef
11.
Zurück zum Zitat Hanberger H, Giske CG, Giamarello H. When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock. Curr Infect Dis Rep. 2011;31(5):416–25.CrossRef Hanberger H, Giske CG, Giamarello H. When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock. Curr Infect Dis Rep. 2011;31(5):416–25.CrossRef
12.•
Zurück zum Zitat Pop-Vicas A, Opal SM. The clinical impact of multidrug resistant gram-negative bacilli in the management of septic shock. Virulence. 2014;5(1):1–7. This review paper discusses the problem of multidrug resistant bacterial pathogens and provides some recommendations on how to treat these infections in criticall ill patients.CrossRef Pop-Vicas A, Opal SM. The clinical impact of multidrug resistant gram-negative bacilli in the management of septic shock. Virulence. 2014;5(1):1–7. This review paper discusses the problem of multidrug resistant bacterial pathogens and provides some recommendations on how to treat these infections in criticall ill patients.CrossRef
13.
Zurück zum Zitat Dellinger RP, Levy MM, Rhodes A, et al. The surviving sepsis guidelines: 2012. Crit Care Med. 2013;41:580–637.CrossRefPubMed Dellinger RP, Levy MM, Rhodes A, et al. The surviving sepsis guidelines: 2012. Crit Care Med. 2013;41:580–637.CrossRefPubMed
14.
Zurück zum Zitat Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association of supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–51.PubMed Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association of supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–51.PubMed
15.
Zurück zum Zitat Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975;135:715–9.CrossRefPubMed Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975;135:715–9.CrossRefPubMed
16.
Zurück zum Zitat Sepkowitz KA. Treatment of patients with hematologic neoplasm, fever, neutropenia. Clin Infect Dis. 2005;40 suppl 4:S253–256.CrossRefPubMed Sepkowitz KA. Treatment of patients with hematologic neoplasm, fever, neutropenia. Clin Infect Dis. 2005;40 suppl 4:S253–256.CrossRefPubMed
17.
Zurück zum Zitat Rolston KV. Challenges in the treatment of gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis. 2005;40 suppl 4:S246–252.CrossRefPubMed Rolston KV. Challenges in the treatment of gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis. 2005;40 suppl 4:S246–252.CrossRefPubMed
18.
Zurück zum Zitat Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986;315:552–8.CrossRefPubMed Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986;315:552–8.CrossRefPubMed
19.
Zurück zum Zitat Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev. 2003;(3):CD003038. Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev. 2003;(3):CD003038.
20.
Zurück zum Zitat Vardakas KZ, Samonis G, Chrysanthopoulou SA, et al. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomized controlled trials. Lancet Infect Dis. 2005;5(7):431–9.CrossRefPubMed Vardakas KZ, Samonis G, Chrysanthopoulou SA, et al. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomized controlled trials. Lancet Infect Dis. 2005;5(7):431–9.CrossRefPubMed
21.•
Zurück zum Zitat Paul M, Dickstein Y, Borok S, et al. Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic with cancer. Cochrane Database Syst Rev. 2014;1:CD003914. This systematic review finds that the addition of empiric antibiotics that target gram-positive bacterial pathogens does not result in improved survival rates in febrile neutropenic patients when compared to antibacterial regimens that initiate coverage of these pathogens only after their presence are documented by bacterial cultures.PubMed Paul M, Dickstein Y, Borok S, et al. Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic with cancer. Cochrane Database Syst Rev. 2014;1:CD003914. This systematic review finds that the addition of empiric antibiotics that target gram-positive bacterial pathogens does not result in improved survival rates in febrile neutropenic patients when compared to antibacterial regimens that initiate coverage of these pathogens only after their presence are documented by bacterial cultures.PubMed
22.
Zurück zum Zitat Bow EJ. Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Semin Hematol. 2009;46:259–68.CrossRefPubMed Bow EJ. Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Semin Hematol. 2009;46:259–68.CrossRefPubMed
23.
Zurück zum Zitat Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–226.CrossRefPubMed Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–226.CrossRefPubMed
25.•
Zurück zum Zitat Opal SM, van der Poll T. Endothelial barrier dysfunction in septic shock. J Intern Med. 2014. doi:10.1111./joim.12331. This basic review details the nature of the endothelial barrier in the microcirculation and the factors that disupt the barrier function in septic shock. New molecular targets have been recently identified that might offer new treatment options for immunocompromised patients with septic shock. Opal SM, van der Poll T. Endothelial barrier dysfunction in septic shock. J Intern Med. 2014. doi:10.​1111.​/​joim.​12331. This basic review details the nature of the endothelial barrier in the microcirculation and the factors that disupt the barrier function in septic shock. New molecular targets have been recently identified that might offer new treatment options for immunocompromised patients with septic shock.
26.
Zurück zum Zitat Skvarc M, Stubjar D, Rogina P, Kaasch AJ. Non-culture-based methods to diagnose bloodstream infections: does it work? Eur J Microbiol Immunol. 2013;3(2):97–104.CrossRef Skvarc M, Stubjar D, Rogina P, Kaasch AJ. Non-culture-based methods to diagnose bloodstream infections: does it work? Eur J Microbiol Immunol. 2013;3(2):97–104.CrossRef
27.
Zurück zum Zitat Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7:338–48.CrossRefPubMed Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7:338–48.CrossRefPubMed
28.
Zurück zum Zitat Kim PM, Wu YT, Cooper C, et al. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis. 2010;51:381–9.CrossRefPubMed Kim PM, Wu YT, Cooper C, et al. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis. 2010;51:381–9.CrossRefPubMed
29.
Zurück zum Zitat Kalil AC. Is cefepime safe for clinical use? A Bayesian viewpoint. J Antimicrob Chemother. 2011;66:1207–9.CrossRefPubMed Kalil AC. Is cefepime safe for clinical use? A Bayesian viewpoint. J Antimicrob Chemother. 2011;66:1207–9.CrossRefPubMed
30.
Zurück zum Zitat Carlet J, Cohen J, Calandra T, Opal SM, Masur H. Sepsis, time to reconsider the concept. Crit Care Med. 2008;36(3):964–7.CrossRefPubMed Carlet J, Cohen J, Calandra T, Opal SM, Masur H. Sepsis, time to reconsider the concept. Crit Care Med. 2008;36(3):964–7.CrossRefPubMed
31.
Zurück zum Zitat Vincent J-L, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet. 2013;381:774–5.CrossRefPubMed Vincent J-L, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet. 2013;381:774–5.CrossRefPubMed
32.•
Zurück zum Zitat Opal SM, Dellinger RP, Vincent J-L, Masur H, Angus DC. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C? Crit Care Med. 2014;42:1714–21. This clinical review discusses the difficulties encountered in the study of new anti-sepsis drugs in clinical trials and offers some suggestions on how to improve future clinical trials.CrossRefPubMed Opal SM, Dellinger RP, Vincent J-L, Masur H, Angus DC. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C? Crit Care Med. 2014;42:1714–21. This clinical review discusses the difficulties encountered in the study of new anti-sepsis drugs in clinical trials and offers some suggestions on how to improve future clinical trials.CrossRefPubMed
33.••
Zurück zum Zitat Deutchman CS, Tracey KJ. Sepsis: current dogma and new perspectives. Immunity. 2014;40:463–75. This is an excellent review of the current understanding of the molecular mechanisms that result in septic shock and offers some new ways to address the problem from a mechanistic perspective.CrossRef Deutchman CS, Tracey KJ. Sepsis: current dogma and new perspectives. Immunity. 2014;40:463–75. This is an excellent review of the current understanding of the molecular mechanisms that result in septic shock and offers some new ways to address the problem from a mechanistic perspective.CrossRef
34.•
Zurück zum Zitat Gomez H, Ince C, DeBacker D, Pickkers P, Payen D, Hotchkiss J, et al. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock. 2014;41(1):3–11. This basic review argues that the problem of sepsis at the cellular level is that cells functionallly loose their ability to maintain their specialized functions in tissues and retreat into a de-differentiated state for individual cell survival.CrossRefPubMedCentralPubMed Gomez H, Ince C, DeBacker D, Pickkers P, Payen D, Hotchkiss J, et al. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock. 2014;41(1):3–11. This basic review argues that the problem of sepsis at the cellular level is that cells functionallly loose their ability to maintain their specialized functions in tissues and retreat into a de-differentiated state for individual cell survival.CrossRefPubMedCentralPubMed
35.•
Zurück zum Zitat Mehta D, Ravindran K, Kuebler W. Novel regulators of endothelial barrier function. Am J Physiol Lung Cell Mol Physiol. 2014;307:L924–35. This paper reviews the structure and function of intercellular gap junctions between endothelial cells in health and disease.CrossRefPubMed Mehta D, Ravindran K, Kuebler W. Novel regulators of endothelial barrier function. Am J Physiol Lung Cell Mol Physiol. 2014;307:L924–35. This paper reviews the structure and function of intercellular gap junctions between endothelial cells in health and disease.CrossRefPubMed
36.
Zurück zum Zitat Kumar A, Paladugu B, Haery C, et al. Timing of antibiotic administration in relation to duration of shock is a critical determinant of survival in a murine model of E. coli sepsis: association with serum lactate and inflammatory cytokines. J Infect Dis. 2006;193:251–8.CrossRefPubMed Kumar A, Paladugu B, Haery C, et al. Timing of antibiotic administration in relation to duration of shock is a critical determinant of survival in a murine model of E. coli sepsis: association with serum lactate and inflammatory cytokines. J Infect Dis. 2006;193:251–8.CrossRefPubMed
38.•
Zurück zum Zitat Chahin A, Opal S, Zorzopulos J, et al. The novel immunotherapeutic oligodeoxynucleotide IMT504 protects neutropenic animals from fatal Pseudomonas aeruginosa bacteremia and sepsis. Antimicrob Agents Chemother. 2015;59(2):1225–9. This experimental study demonstrates that specific short sequences of oligonucleotides can function as immunostimulants and improve the prognosis of experimental animals with febrile neutropenic systemic infections. Whether this strategy will work in neutropenic sepsis remains to be tested in clinical trials.CrossRefPubMed Chahin A, Opal S, Zorzopulos J, et al. The novel immunotherapeutic oligodeoxynucleotide IMT504 protects neutropenic animals from fatal Pseudomonas aeruginosa bacteremia and sepsis. Antimicrob Agents Chemother. 2015;59(2):1225–9. This experimental study demonstrates that specific short sequences of oligonucleotides can function as immunostimulants and improve the prognosis of experimental animals with febrile neutropenic systemic infections. Whether this strategy will work in neutropenic sepsis remains to be tested in clinical trials.CrossRefPubMed
39.
Zurück zum Zitat Kalil AC, Dakroub H, Freifeld AG. Sepsis and solid organ transplantation. Curr Drug Targets. 2007;8(4):533–41.CrossRefPubMed Kalil AC, Dakroub H, Freifeld AG. Sepsis and solid organ transplantation. Curr Drug Targets. 2007;8(4):533–41.CrossRefPubMed
40.
Zurück zum Zitat Trzeciak S, Sharer R, Piper D, et al. Infections and severe sepsis in solid-organ transplant patients admitted from a university-based ED. The Am J Emergency Med. 2004;22(7):530–3.CrossRef Trzeciak S, Sharer R, Piper D, et al. Infections and severe sepsis in solid-organ transplant patients admitted from a university-based ED. The Am J Emergency Med. 2004;22(7):530–3.CrossRef
41.
Zurück zum Zitat Hsu RB, Chang CI, Fang CT, Chang SC, Wang SS, Chu SH. Bloodstream infection in heart transplant recipients: 12-year experience at a university hospital in Taiwan. Euro J Cardio-Thoracic Surg. 2011;40(6):1362–7. Hsu RB, Chang CI, Fang CT, Chang SC, Wang SS, Chu SH. Bloodstream infection in heart transplant recipients: 12-year experience at a university hospital in Taiwan. Euro J Cardio-Thoracic Surg. 2011;40(6):1362–7.
42.
Zurück zum Zitat Candel FJ, Grima E, Matesanz M, et al. Bacteremia and septic shock after solid-organ transplantation. Transplantation Proc. 2005;37(9):4097–9.CrossRef Candel FJ, Grima E, Matesanz M, et al. Bacteremia and septic shock after solid-organ transplantation. Transplantation Proc. 2005;37(9):4097–9.CrossRef
43.
Zurück zum Zitat Wan Q, Ye Q, Zhou J. Mortality predictors of bloodstream infections in solid-organ transplant recipients. Exp Clin Trans. 2013;11(3):211–4.CrossRef Wan Q, Ye Q, Zhou J. Mortality predictors of bloodstream infections in solid-organ transplant recipients. Exp Clin Trans. 2013;11(3):211–4.CrossRef
44.
Zurück zum Zitat Bodro M, Sabe N, Tubau F, et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation. 2013;96(9):843–9. This study analyzed a cohort of solid organ transplant patients who developed bacteremia with ESKAPE organisms and concluded that the following factors were independently associated with ESKAPE infection: prior transplantation, septic shock, and prior antibiotic therapy.CrossRefPubMed Bodro M, Sabe N, Tubau F, et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation. 2013;96(9):843–9. This study analyzed a cohort of solid organ transplant patients who developed bacteremia with ESKAPE organisms and concluded that the following factors were independently associated with ESKAPE infection: prior transplantation, septic shock, and prior antibiotic therapy.CrossRefPubMed
45.
Zurück zum Zitat Linares L, Garcia-Goez JF, Cervera C, Almela M, Sanclemente G, Cofan F, et al. Early bacteremia after solid organ transplantation. Trans Proc. 2009;41(6):2262–4.CrossRef Linares L, Garcia-Goez JF, Cervera C, Almela M, Sanclemente G, Cofan F, et al. Early bacteremia after solid organ transplantation. Trans Proc. 2009;41(6):2262–4.CrossRef
46.
Zurück zum Zitat Malinis MF, Mawhorter SD, Jain A, Shrestha NK, Avery RK, van Duin D. Staphylococcus aureus bacteremia in solid organ transplant recipients: evidence for improved survival when compared with nontransplant patients. Transplantation. 2012;93(10):1045–50.CrossRefPubMed Malinis MF, Mawhorter SD, Jain A, Shrestha NK, Avery RK, van Duin D. Staphylococcus aureus bacteremia in solid organ transplant recipients: evidence for improved survival when compared with nontransplant patients. Transplantation. 2012;93(10):1045–50.CrossRefPubMed
48.
Zurück zum Zitat van Hal SJ, Marriott DJ, Chen SC, Nguyen Q, Sorrell TC, Ellis DH, et al. Candidemia following solid organ transplantation in the era of antifungal prophylaxis: the Australian experience. Trans Infect Dis. 2009;11(2):122–7.CrossRef van Hal SJ, Marriott DJ, Chen SC, Nguyen Q, Sorrell TC, Ellis DH, et al. Candidemia following solid organ transplantation in the era of antifungal prophylaxis: the Australian experience. Trans Infect Dis. 2009;11(2):122–7.CrossRef
49.
Zurück zum Zitat Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med. 2005;143(12):870–80.CrossRefPubMed Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med. 2005;143(12):870–80.CrossRefPubMed
50.
Zurück zum Zitat Chuang P, Parikh CR, Langone A. Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers. Clin Trans. 2005;19(2):230–5.CrossRef Chuang P, Parikh CR, Langone A. Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers. Clin Trans. 2005;19(2):230–5.CrossRef
51.
Zurück zum Zitat Schmaldienst S, Dittrich E, Horl WH. Urinary tract infections after renal transplantation. Curr Opin Urol. 2002;12(2):125–30.CrossRefPubMed Schmaldienst S, Dittrich E, Horl WH. Urinary tract infections after renal transplantation. Curr Opin Urol. 2002;12(2):125–30.CrossRefPubMed
52.
Zurück zum Zitat Wagener MM, Yu VL. Bacteremia in transplant recipients: a prospective study of demographics, etiologic agents, risk factors, and outcomes. Am J Infect Control. 1992;20(5):239–47.CrossRefPubMed Wagener MM, Yu VL. Bacteremia in transplant recipients: a prospective study of demographics, etiologic agents, risk factors, and outcomes. Am J Infect Control. 1992;20(5):239–47.CrossRefPubMed
53.
Zurück zum Zitat Warren JW, Platt R, Thomas RJ, Rosner B, Kass EH. Antibiotic irrigation and catheter-associated urinary-tract infections. N Engl J Med. 1978;299(11):570–3.CrossRefPubMed Warren JW, Platt R, Thomas RJ, Rosner B, Kass EH. Antibiotic irrigation and catheter-associated urinary-tract infections. N Engl J Med. 1978;299(11):570–3.CrossRefPubMed
54.
Zurück zum Zitat Koneru B, Selby R, O’Hair DP, Tzakis AG, Hakala TR, Starzl TE. Nonobstructing colonic dilatation and colon perforations following renal transplantation. Arch Surg. 1990;125(5):610–3.CrossRefPubMedCentralPubMed Koneru B, Selby R, O’Hair DP, Tzakis AG, Hakala TR, Starzl TE. Nonobstructing colonic dilatation and colon perforations following renal transplantation. Arch Surg. 1990;125(5):610–3.CrossRefPubMedCentralPubMed
55.
Zurück zum Zitat Andreoni KA, Pelletier RP, Elkhammas EA, et al. Increased incidence of gastrointestinal surgical complications in renal transplant recipients with polycystic kidney disease. Transplantation. 1999;67(2):262–6.CrossRefPubMed Andreoni KA, Pelletier RP, Elkhammas EA, et al. Increased incidence of gastrointestinal surgical complications in renal transplant recipients with polycystic kidney disease. Transplantation. 1999;67(2):262–6.CrossRefPubMed
56.
Zurück zum Zitat Dominguez Fernandez E, Albrecht KH, et al. Prevalence of diverticulosis and incidence of bowel perforation after kidney transplantation in patients with polycystic kidney disease. Transpl Int. 1998;11(1):28–31.CrossRefPubMed Dominguez Fernandez E, Albrecht KH, et al. Prevalence of diverticulosis and incidence of bowel perforation after kidney transplantation in patients with polycystic kidney disease. Transpl Int. 1998;11(1):28–31.CrossRefPubMed
57.
Zurück zum Zitat Abbott KC, Oliver 3rd JD, Hypolite I, et al. Hospitalizations for bacterial septicemia after renal transplantation in the United States. Am J Nephrol. 2001;21(2):120–7.CrossRefPubMed Abbott KC, Oliver 3rd JD, Hypolite I, et al. Hospitalizations for bacterial septicemia after renal transplantation in the United States. Am J Nephrol. 2001;21(2):120–7.CrossRefPubMed
58.
59.
Zurück zum Zitat George DL, Arnow PM, Fox AS, et al. Bacterial infection as a complication of liver transplantation: epidemiology and risk factors. Rev Infect Dis. 1991;13(3):387–96.CrossRefPubMed George DL, Arnow PM, Fox AS, et al. Bacterial infection as a complication of liver transplantation: epidemiology and risk factors. Rev Infect Dis. 1991;13(3):387–96.CrossRefPubMed
60.
Zurück zum Zitat Koivusalo A, Isoniemi H, Salmela K, Hockerstedt K. Biliary complications in 100 adult liver transplantations: a retrospective clinical study. Transpl Int. 1994;7 Suppl 1:S119–20.CrossRefPubMed Koivusalo A, Isoniemi H, Salmela K, Hockerstedt K. Biliary complications in 100 adult liver transplantations: a retrospective clinical study. Transpl Int. 1994;7 Suppl 1:S119–20.CrossRefPubMed
61.
Zurück zum Zitat Collins LA, Samore MH, Roberts MS, Luzzati R, Jenkins RL, Lewis WD, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis. 1994;170(3):644–52.CrossRefPubMed Collins LA, Samore MH, Roberts MS, Luzzati R, Jenkins RL, Lewis WD, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis. 1994;170(3):644–52.CrossRefPubMed
62.
Zurück zum Zitat Paya CV, Hermans PE, Washington 2nd JA, et al. Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clinic Proc. 1989;64(5):555–64.CrossRef Paya CV, Hermans PE, Washington 2nd JA, et al. Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clinic Proc. 1989;64(5):555–64.CrossRef
63.
64.
Zurück zum Zitat Newell KA, Millis JM, Arnow PM, et al. Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthotopic liver transplantation. Transplantation. 1998;65(3):439–42.CrossRefPubMed Newell KA, Millis JM, Arnow PM, et al. Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthotopic liver transplantation. Transplantation. 1998;65(3):439–42.CrossRefPubMed
65.
Zurück zum Zitat Tachopoulou OA, Vogt DP, Henderson JM, Baker M, Keys TF. Hepatic abscess after liver transplantation: 1990-2000. Transplantation. 2003;75(1):79–83.CrossRefPubMed Tachopoulou OA, Vogt DP, Henderson JM, Baker M, Keys TF. Hepatic abscess after liver transplantation: 1990-2000. Transplantation. 2003;75(1):79–83.CrossRefPubMed
66.•
Zurück zum Zitat Hsu JL, Enser JJ, McKown T, et al. Outcomes of Clostridium difficile infection in recipients of solid abdominal organ transplants. Clin Trans. 2014;28(2):267–73. This study evaluated solid organ transplant patients who developed Clostridium difficile infection and found that the risk factors for clinical failure at 14 days were vasopressor support, previous Clostridium difficile infection, and treatment with vancomycin. Three-quarters of all transplant patients were clinically cured at 14 days.CrossRef Hsu JL, Enser JJ, McKown T, et al. Outcomes of Clostridium difficile infection in recipients of solid abdominal organ transplants. Clin Trans. 2014;28(2):267–73. This study evaluated solid organ transplant patients who developed Clostridium difficile infection and found that the risk factors for clinical failure at 14 days were vasopressor support, previous Clostridium difficile infection, and treatment with vancomycin. Three-quarters of all transplant patients were clinically cured at 14 days.CrossRef
67.
Zurück zum Zitat Tsapepas DS, Martin ST, Miao J, et al. Clostridium difficile infection, a descriptive analysis of solid organ transplant recipients at a single center. Diagn Microbiol Infect Dis. 2014;80(4):239–344 Tsapepas DS, Martin ST, Miao J, et al. Clostridium difficile infection, a descriptive analysis of solid organ transplant recipients at a single center. Diagn Microbiol Infect Dis. 2014;80(4):239–344
68.
Zurück zum Zitat Corensek MJ, Stewart RW, Keys TF, Mehta AC, McHenry MC, Goormastic M. A multivariate analysis of risk factors for pneumonia following cardiac transplantation. Transplantation. 1988;46(6):860–5.CrossRefPubMed Corensek MJ, Stewart RW, Keys TF, Mehta AC, McHenry MC, Goormastic M. A multivariate analysis of risk factors for pneumonia following cardiac transplantation. Transplantation. 1988;46(6):860–5.CrossRefPubMed
69.
Zurück zum Zitat Cisneros JM, Munoz P, Torre-Cisneros J, et al. Pneumonia after heart transplantation: a multi-institutional study. Spanish Transplantation Infection Study Group. Clin Infect Dis. 1998;27(2):324–31.CrossRefPubMed Cisneros JM, Munoz P, Torre-Cisneros J, et al. Pneumonia after heart transplantation: a multi-institutional study. Spanish Transplantation Infection Study Group. Clin Infect Dis. 1998;27(2):324–31.CrossRefPubMed
70.
Zurück zum Zitat Myers TJ, Khan T, Frazier OH. Infectious complications associated with ventricular assist systems. ASAIO J. 2000;46(6):S28–36.CrossRefPubMed Myers TJ, Khan T, Frazier OH. Infectious complications associated with ventricular assist systems. ASAIO J. 2000;46(6):S28–36.CrossRefPubMed
71.
Zurück zum Zitat Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis. 2001;33(5):629–40.CrossRefPubMed Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis. 2001;33(5):629–40.CrossRefPubMed
72.
Zurück zum Zitat Hofflin JM, Potasman I, Baldwin JC, Oyer PE, Stinson EB, Remington JS. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Intern Med. 1987;106(2):209–16.CrossRefPubMed Hofflin JM, Potasman I, Baldwin JC, Oyer PE, Stinson EB, Remington JS. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Intern Med. 1987;106(2):209–16.CrossRefPubMed
73.
Zurück zum Zitat Horvath J, Dummer S, Loyd J, Walker B, Merrill WH, Frist WH. Infection in the transplanted and native lung after single lung transplantation. Chest. 1993;104(3):681–5.CrossRefPubMed Horvath J, Dummer S, Loyd J, Walker B, Merrill WH, Frist WH. Infection in the transplanted and native lung after single lung transplantation. Chest. 1993;104(3):681–5.CrossRefPubMed
74.
Zurück zum Zitat Kramer MR, Marshall SE, Starnes VA, Gamberg P, Amitai Z, Theodore J. Infectious complications in heart-lung transplantation. Analysis of 200 episodes. Arch Intern Med. 1993;153(17):2010–6.CrossRefPubMed Kramer MR, Marshall SE, Starnes VA, Gamberg P, Amitai Z, Theodore J. Infectious complications in heart-lung transplantation. Analysis of 200 episodes. Arch Intern Med. 1993;153(17):2010–6.CrossRefPubMed
75.
Zurück zum Zitat Maurer JR, Tullis DE, Grossman RF, Vellend H, Winton TL, Patterson GA. Infectious complications following isolated lung transplantation. Chest. 1992;101(4):1056–9.CrossRefPubMed Maurer JR, Tullis DE, Grossman RF, Vellend H, Winton TL, Patterson GA. Infectious complications following isolated lung transplantation. Chest. 1992;101(4):1056–9.CrossRefPubMed
76.
Zurück zum Zitat Hadjiliadis D, Sporn TA, Perfect JR, Tapson VF, Davis RD, Palmer SM. Outcome of lung transplantation in patients with mycetomas. Chest. 2002;121(1):128–34.CrossRefPubMed Hadjiliadis D, Sporn TA, Perfect JR, Tapson VF, Davis RD, Palmer SM. Outcome of lung transplantation in patients with mycetomas. Chest. 2002;121(1):128–34.CrossRefPubMed
77.
Zurück zum Zitat Smith PC, Slaughter MS, Petty MG, Shumway SJ, Kshettry VR, Bolman RM, 3rd. Abdominal complications after lung transplantation. J Heart Lung Transplantation 1995;14:44–51 Smith PC, Slaughter MS, Petty MG, Shumway SJ, Kshettry VR, Bolman RM, 3rd. Abdominal complications after lung transplantation. J Heart Lung Transplantation 1995;14:44–51
78.
Zurück zum Zitat Venuta F, Boehler A, Rendina EA, et al. Complications in the native lung after single lung transplantation. Euro J Cardio-Thoracic Surg. 1999;16(1):54–8.CrossRef Venuta F, Boehler A, Rendina EA, et al. Complications in the native lung after single lung transplantation. Euro J Cardio-Thoracic Surg. 1999;16(1):54–8.CrossRef
79.
Zurück zum Zitat Stewart S, McNeil K, Nashef SA, Wells FC, Higenbottam TW, Wallwork J. Audit of referral and explant diagnoses in lung transplantation: a pathologic study of lungs removed for parenchymal disease. J Heart Lung Trans. 1995;14(6 Pt 1):1173–86. Stewart S, McNeil K, Nashef SA, Wells FC, Higenbottam TW, Wallwork J. Audit of referral and explant diagnoses in lung transplantation: a pathologic study of lungs removed for parenchymal disease. J Heart Lung Trans. 1995;14(6 Pt 1):1173–86.
Metadaten
Titel
Sepsis in the Severely Immunocompromised Patient
verfasst von
Andre C. Kalil
Steven M. Opal
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Current Infectious Disease Reports / Ausgabe 6/2015
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-015-0487-4

Weitere Artikel der Ausgabe 6/2015

Current Infectious Disease Reports 6/2015 Zur Ausgabe

Intra-abdominal Infections, Hepatitis, and Gastroenteritis (T Steiner, Section Editor)

Epidemiology and Treatment of Trichomoniasis

Healthcare Associated Infections (G Bearman and D Morgan, Section Editors)

The Pros, Cons, and Unknowns of Search and Destroy for Carbapenem-Resistant Enterobacteriaceae

Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

The Swiss Transplant Cohort Study: Lessons from the First 6 Years

Genitourinary Infections (J Sobel, Section Editor)

Vulvovaginal Candidiasis in Pregnancy

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.